top of page
PleoPharma, Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial of PP-01 (CAN-004) for Mitigation of Cannabis Withdrawal Symptoms in Patients with Cannabis Use Disorder
Phase 3 trial initiation advances PP-01, an investigational, once-daily therapy for cannabis withdrawal symptoms in patients with cannabis use disorder
PleoPharma, Inc.
Jun 18
PLEOPHARMA TO PRESENT NEWDATA ON CANNABIS WITHDRAWAL In PATIENTS WITH CANNABIS USE DISORDER AND PHASE 2 PP-01 RESULTS AT THE COLLEGE ON PROBLEMS OF DRUG DEPENDENCE 88TH ANNUAL SCIENTIFIC MEETING
Presentations will highlight the patient experience of cannabis withdrawal/cannabis use disorder and Phase 2 CAN-002 data for investigational PP-01 in adults with cannabis use disorder PHOENIXVILLE, Pa., June 15, 2026 /PRNewswire/ -- PleoPharma, a clinical-stage clinical development company focused on cannabis-related health issues, announced today that it will present two posters at the College on Problems of Drug Dependence (CPDD) 88th Annual Scientific Meeting, taking plac
PleoPharma, Inc.
Jun 15
PLEOPHARMA, INC. to Present at the Centri Capital Conference in New York
PleoPharma, Inc., a privately held company focused on finding treatments for cannabis related health issues, announced today that management will present at the Centri Capital Conference in New York City on April 14, 2026 at 8:30 a.m. Eastern Time (ET).
PleoPharma, Inc.
Mar 30
PleoPharma, Inc. Closes $36 Million Series B Financing Round
Phoenixville, pa, October 21, 2025 – PleoPharma, Inc., a privately held company focused on finding treatments for cannabis-related health issues, announced today the closing of a $36MM Series B financing round.
PleoPharma, Inc.
Oct 21, 2025
PLEOPHARMA, INC. Presents Positive Cannabis Withdrawal Clinical Trial Results at The College on Problems of Drug Dependence Annual Meeting
PleoPharma, Inc., a privately held company focused on cannabis-related health issues, announced today, the presentation of data from their Phase 2b multicenter, randomized, double-blind, multi-dose, placebo-controlled clinical trial of titrating doses of PP-01 for the mitigation of Cannabis Withdrawal Syndrome (CWS) in participants with Cannabis Use Disorder (CUD) at the 2025 annual meeting of The College on Problems of Drug Dependence in New Orleans, LA.
PleoPharma, Inc.
Jun 19, 2025
PLEOPHARMA, INC. Reports New Patent Issuance
New Patent Issued on April 8, 2025 Patent Protection to March 2041 PHOENIXVILLE, Pa., April 16, 2025 /PRNewswire/ -- PleoPharma, Inc....
PleoPharma, Inc.
Apr 16, 2025
FDA GRANTS FAST TRACK DESIGNATION TO PLEOPHARMA, INC's INVESTIGATIONAL NEW DRUG, PP-01, FOR THE MITIGATION OF CANNABIS WITHDRAWAL SYMPTOMS IN PATIENTS WITH CANNABIS USE DISORDER:
A POTENTIAL FIRST IN TREATMENT Fast Track Designation highlights the potential of PP-01 to address a serious and unmet need for patients...
PleoPharma, Inc.
Feb 13, 2025
AAAP Poster - November 2024
PP-01 Reduced Symptoms of Cannabis Withdrawal in a Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Clinical Trial
PleoPharma, Inc.
Nov 18, 2024
PLEOPHARMA, INC. Presents Positive Cannabis Withdrawal Clinical Trial Results at AAAP Annual Meeting
PHOENIXVILLE, Pa., Nov. 18, 2024 /PRNewswire/ -- PleoPharma, Inc., a privately held company focused on cannabis-related health issues
PleoPharma, Inc.
Nov 18, 2024
bottom of page